Stockscreener 앱 받기
150.29
1.69%
2.565
전일 마감가:
$147.73
열려 있는:
$148.1
하루 거래량:
160.62K
Relative Volume:
0.45
시가총액:
$4.34B
수익:
$290.51M
순이익/손실:
$89.16M
주가수익비율:
50.27
EPS:
2.99
순현금흐름:
$119.18M
1주 성능:
+0.89%
1개월 성능:
+12.92%
6개월 성능:
+3.74%
1년 성능:
-27.96%
1일 변동 폭
$147.14
$151.79
1주일 범위
$146.42
$152.05
52주 변동 폭
$122.80
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
명칭
Krystal Biotech Inc
전화
(412) 586-5830
주소
2100 WHARTON STREET, PITTSBURGH, PA
KRYS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
150.22 | 4.14B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.45 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.40 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.00 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.40 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
278.19 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 개시 | Jefferies | Buy |
| 2024-08-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-12 | 개시 | Citigroup | Buy |
| 2023-09-07 | 개시 | Berenberg | Buy |
| 2023-04-18 | 개시 | Stifel | Buy |
| 2023-02-28 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-01-18 | 개시 | BofA Securities | Buy |
| 2021-07-20 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-18 | 개시 | B. Riley FBR | Buy |
| 2020-06-04 | 개시 | Evercore ISI | Outperform |
| 2019-09-24 | 개시 | Goldman | Neutral |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-24 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-30 | 개시 | Guggenheim | Buy |
| 2018-09-11 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Krystal Biotech Inc 주식(KRYS)의 최신 뉴스
Krystal Biotech, Inc. (NASDAQ:KRYS) Position Trimmed by Bank of New York Mellon Corp - Defense World
why krystal biotech inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Newser
M&T Bank Corp Purchases New Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech FY2025 EPS Estimate Lowered by William Blair - Defense World
Why Krystal Biotech Inc. stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser
What makes Krystal Biotech Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser
How Krystal Biotech Inc. stock performs during market volatilityFree Capital Growth Strategies - Newser
Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis - Ophthalmology Times
Teacher Retirement System of Texas Has $1.05 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
William Blair Forecasts Lower Earnings for Krystal Biotech - Defense World
William Blair Expects Lower Earnings for Krystal Biotech - Defense World
Krystal Biotech begins phase 1/2 trial of eye drop gene therapy for NK By Investing.com - Investing.com South Africa
Transcript : Krystal Biotech, Inc.Special Call - MarketScreener
Krystal Biotech Begins Phase 1/2 Trial for KB801 - TipRanks
Krystal Biotech Initiates First Patient Dosing in Phase 1/2 EMERALD-1 Trial for KB801 in Neurotrophic Keratitis - Nasdaq
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis - TradingView
Revolutionary Eye Drop Gene Therapy: Krystal Biotech Targets 68,000 Patient NK Market in New Trial - Stock Titan
New York State Teachers Retirement System Grows Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Allspring Global Investments Holdings LLC Decreases Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Amalgamated Bank - Defense World
Vontobel Holding Ltd. Sells 284 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Exploring High Growth Tech Stocks In The US Market - Yahoo Finance
Long Term Trading Analysis for (KRYS) - news.stocktradersdaily.com
GAMMA Investing LLC Acquires 432 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech (NASDAQ:KRYS) shareholder returns have been strong, earning 249% in 5 years - simplywall.st
Q2 EPS Estimates for Krystal Biotech Cut by HC Wainwright - Defense World
Krystal Biotech, Inc.'s (NASDAQ:KRYS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - Yahoo Finance
Krystal Biotech FY2026 EPS Estimate Reduced by HC Wainwright - Defense World
Dino A Rossi Exhibits Confidence With An Acquisition Of Krystal Biotech Stock Options Worth $6K - Nasdaq
Oppenheimer Asset Management Inc. Purchases New Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech, Inc.(NasdaqGS: KRYS) added to Russell 2000 Growth-Defensive Index - MarketScreener
H.C. Wainwright reiterates Buy rating on Krystal Biotech stock ahead of Q2 results - Investing.com Canada
Krystal Biotech, Inc.(NasdaqGS: KRYS) added to Russell 2000 Defensive Index - MarketScreener
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $211.13 Average Target Price from Brokerages - Defense World
3 Promising Genomics Stocks to Keep an Eye On in 2025 - The Globe and Mail
KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study - Yahoo Finance
Gene Therapy Market Top Companies Study -Krystal Biotech, Inc., - openPR.com
Fifth Third Bancorp Buys 105 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga
Yousif Capital Management LLC Trims Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Abeona Therapeutics' Zevaskyn Vs. Krystal Biotech's Vyjuvek (KRYS, ABEO) - Seeking Alpha
Krystal Biotech (NASDAQ:KRYS) and VectivBio (NASDAQ:VECT) Critical Review - Defense World
Breakthrough Innovations Drive Booming U.S. Gene Therapy - openPR.com
Cantor Fitzgerald Estimates Krystal Biotech FY2026 Earnings - Defense World
Krystal Biotech at Goldman Sachs Conference: Strategic Insights on VYJEVEC - Investing.com Canada
Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report? - Yahoo Finance
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
H.C. Wainwright maintains Krystal Biotech stock Buy rating at ASCO 2025 - Investing.com Nigeria
Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
How To Trade (KRYS) - news.stocktradersdaily.com
Krystal Biotech Reports Promising Results for KB707 Trial - TipRanks
Krystal Biotech Inc (KRYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.03%
2.09%
자본화:
|
볼륨(24시간):